Invitae Corporation (NYSE:NVTA) genetic information outfit, is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.7 per share.
Looking ahead, the full year loss are expected at $ 2.74 per share on the revenues of $ 260.03 million.
Previous Quarter Performance
Invitae Corporation announced loss for the first quarter of $ 0.80 per share, from the revenue of $ 64.25 million. The quarterly revenues surged 58.45 percent compared with the same quarter last year. Street analysts expected Invitae Corporation to report loss of $ 0.79 per share on revenue of $ 59.41 million for the first quarter. The bottom line results missed street analysts by $ 0.01 or 1.27 percent, at the same time, top line results outshined analysts by $ 4.84 million or 8.15 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Invitae Corporation
Stock Performance
According to the previous trading day, closing price of NVTA was $ 32.07, representing a 332.21 % increase from the 52 week low of $ 7.42 and a 9.23 % decrease over the 52 week high of $ 35.33.
The company has a market capital of $ 4.01 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NVTA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 1st July 2020, downgraded by Benchmark to Hold from Buy rating.
Conference Call
Invitae Corporation will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.invitae.com
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information.
